The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth

BACKGROUND: Kirsten rat sarcoma (KRAS) protein is an essential contributor to the development of pancreatic ductal adenocarcinoma (PDAC). KRAS G12D and G12V mutant tumours are significant challenges in cancer therapy due to high resistance to the treatment. OBJECTIVE: To determine how effective is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Begimbetova, Dinara, Kukanova, Assiya, Fazyl, Fatima, Manekenova, Kenzhekyz, Omarov, Talgat, Burska, Agata N., Khamijan, Medina, Gulyayev, Alexandr, Yermekbayeva, Bakytgul, Makishev, Abay, Saliev, Timur, Batyrbekov, Kanat, Aitbayev, Chokan, Spatayev, Zhanat, Sarbassov, Dos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822755/
https://www.ncbi.nlm.nih.gov/pubmed/36619305
http://dx.doi.org/10.1155/2022/9426623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822755/
https://www.ncbi.nlm.nih.gov/pubmed/36619305
http://dx.doi.org/10.1155/2022/9426623

Ejemplares similares